ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : ACIDIC DRUGS
Scheme : Project Grants
Clear All
Filter by Field of Research
Psychiatry (incl. Psychotherapy) (4)
Central Nervous System (2)
Clinical Sciences not elsewhere classified (2)
Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology) (1)
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (1)
Cardiology (incl. Cardiovascular Diseases) (1)
Foetal Development and Medicine (1)
Genomics (1)
Medical and Health Sciences (1)
Nephrology and Urology (1)
Oncology and Carcinogenesis not elsewhere classified (1)
Pharmacology and Pharmaceutical Sciences not elsewhere classified (1)
Psychology and Cognitive Sciences not elsewhere classified (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (18)
Filter by Status
Closed (18)
Filter by Scheme
Project Grants (18)
Filter by Country
Australia (3)
Filter by Australian State/Territory
NSW (3)
ACT (1)
WA (1)
  • Researchers (0)
  • Funded Activities (18)
  • Organisations (0)
  • Funded Activity

    Whole Genome Pharmacogenomics Study Of Susceptibility Of Birth Defects In Children Born To Mothers Taking Anti-Epileptic Drugs

    Funder
    National Health and Medical Research Council
    Funding Amount
    $663,160.00
    Summary
    This project will investigate for genes that determine why certain women have an increased risk of having a baby with a birth defect if they become pregnant while being treated with a medication for epilepsy. Subjects will be recruited from the Australian Pregnancy Register, the findings validated using subjects from the UK Epilepsy and Pregnancy Register. The study will comprehensively examine for both common and rare changes in genes across the entire human genome.
    More information
    Funded Activity

    Genomics Of Antiepileptic Drug-induced Stevens Johnson Syndrome

    Funder
    National Health and Medical Research Council
    Funding Amount
    $500,817.00
    Summary
    Epilepsy affects 3% of people. Severe skin reactions to anti-epileptic drugs are unpredictable and potentially fatal. This project aims to better understand the complex genetic architecture of these reactions using the latest sequencing platforms applied to a unique collection of samples, followed by functional analysis. The findings will enhance the practice of precision medicine in epilepsy treatment, shed light on the mechanisms of these reactions, and inform better drug design in the future.
    More information
    Funded Activity

    DNase I As Treatment For MPO-ANCA Vasculitis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $880,496.00
    Summary
    MPO-ANCA GN is a major cause of renal failure. Current treatments are toxic and poorly effective. Excessive DNA production resulting in prominent deposits of extracellular DNA are seen in glomeruli of patients with MPO-ANCA GN. This study will look at the pathological role of DNA and in a relevant animal model, use DNase I treatment to dissolve deposited DNA and treat anti-MPO autoimmunity and GN. This evidence will allow the introduction of DNase I in clinical trials.
    More information
    Funded Activity

    Overcoming Barriers To Improved Physical Health In People With Severe Mental Illness

    Funder
    National Health and Medical Research Council
    Funding Amount
    $864,658.00
    Summary
    People with severe mental illness have high rates of cardiometabolic disease and reduced life-expectancy. Public intervention campaigns have had little impact on component risks (obesity, smoking, physical inactivity, poor nutrition). This study will determine factors associated with changes in cardiometabolic profiles in people with severe mental illness; examine impediments to risk modification; and develop targeted interventions for implementation within mental health services.
    More information
    Funded Activity

    Development Of Iron Complexes For The Treatment Of FriedreichÍs Ataxia & The Role Of Frataxin In Iron Metabolism

    Funder
    National Health and Medical Research Council
    Funding Amount
    $616,143.00
    Summary
    Friedreich's ataxia (FA) is a neuro- & cardio-degenerative disease where there is an accumulation of toxic iron (Fe) in the mitochondrion. Work from our current NHMRC grant showed iron plays a significant role in FA pathology In fact, the CIs dissected the mechanisms of mitochondrial iron-loading & have published 8 papers in high impact journals with 3 papers in PNAS USA in the last 2 yrs Understanding of this process has led to the design of rationalised drugs for FA This work in this Renewal c .... Friedreich's ataxia (FA) is a neuro- & cardio-degenerative disease where there is an accumulation of toxic iron (Fe) in the mitochondrion. Work from our current NHMRC grant showed iron plays a significant role in FA pathology In fact, the CIs dissected the mechanisms of mitochondrial iron-loading & have published 8 papers in high impact journals with 3 papers in PNAS USA in the last 2 yrs Understanding of this process has led to the design of rationalised drugs for FA This work in this Renewal could lead to novel therapies for FA
    Read more Read less
    More information
    Funded Activity

    Carbon Dioxide As A Treatment For Seizures In The Newborn

    Funder
    National Health and Medical Research Council
    Funding Amount
    $878,389.00
    Summary
    This study aims to introduce a simple and effective treatment to prevent brain damage from seizures in babies using CO2. Neonatal seizures remain a major clinical problem worldwide and are associated with poor brain outcomes and significant risk of death. Recent trials in human adult epileptics show rapid and effective seizure suppression following the use of CO2. This therapy will significantly impact long-term outcomes for affected babies and reduce the burden of care for families and society.
    More information
    Funded Activity

    The Relationship Between Accident Culpability And Drug Presence In Blood Samples Taken From Persons Injured In Motor Vehicle Collisions.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $200,721.00
    Summary
    This project aims to determine the incidence of drugs in blood samples taken under the Victorian Road Safety Act 1986 from drivers involved in non-fatal collisions, the relative importance of illicit drugs, legal drugs used as prescribed, and legal drugs misused by drivers in non-fatal collisions by examining driver culpability in these accidents.
    More information
    Funded Activity

    Randomised Controlled Trial Of Aripiprazole For Treatment Of Auditory Verbal Hallucinations In Borderline Personality Disorder

    Funder
    National Health and Medical Research Council
    Funding Amount
    $2,748,148.00
    Summary
    People with borderline personality disorder (BPD) often report hearing voices. There is no consensus about how to treat these symptoms. Our study aims to address this clinical problem by conducting a 12 week trial of antipsychotic medication in patients who hear voices and have a diagnosis of BPD. The study will examine the effect of this medication on the nature of these voices, as well as other aspects of mental illness and brain functioning. The results will directly inform clinical practice.
    More information
    Funded Activity

    Understanding The Mechanisms For Ameliorating/preventing Antipsychotic-induced Obesity In Early Life

    Funder
    National Health and Medical Research Council
    Funding Amount
    $576,496.00
    Summary
    There has been a sharp worldwide increase during the last decade in antipsychotic prescriptions (mostly “off-label”) to paediatric patients. One important issue is that antipsychotic drugs were developed for adult patients and normally have serious side-effects. This project will not only reveal the mechanisms of antipsychotic-induced obesity side-effects in youth, but will also explore intervention strategies for preventing antipsychotic-induced weight gain/obesity in paediatric patients.
    More information
    Funded Activity

    Selective Estrogen Receptor Modulators - A New Adjunctive Treatment For Men With Schizophrenia?

    Funder
    National Health and Medical Research Council
    Funding Amount
    $816,603.00
    Summary
    One-third of people with schizophrenia do not respond well to antipsychotic medication treatment.There is an urgent need to develop new treatments.We have conducted world-first studies showing that estrogen treatment is highly successful in treating women with schizophrenia.Our research is a trial of SERM (selective estrogen receptor modulator), a new form of “brain estrogen” in men with persistent schizophrenia. We hope to reduce the disability caused by persistent psychotic symptoms.
    More information

    Showing 1-10 of 18 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback